New Drug Combination Yields Disappointing Results in Mesothelioma Clinical Trial

Research & Clinical Trials
Reading Time: 3 mins
Publication Date: 06/13/2012
Fact Checked
Our fact-checking process begins with a thorough review of all sources to ensure they are high quality. Then we cross-check the facts with original medical or scientific reports published by those sources, or we validate the facts with reputable news organizations, medical and scientific experts and other health experts. Each page includes all sources for full transparency.
Reviewed is the nation’s most trusted mesothelioma resource

The Mesothelioma Center at has provided patients and their loved ones the most updated and reliable information on mesothelioma and asbestos exposure since 2006.

Our team of Patient Advocates includes a medical doctor, a registered nurse, health services administrators, veterans, VA-accredited Claims Agents, an oncology patient navigator and hospice care expert. Their combined expertise means we help any mesothelioma patient or loved one through every step of their cancer journey.

More than 30 contributors, including mesothelioma doctors, survivors, health care professionals and other experts, have peer-reviewed our website and written unique research-driven articles to ensure you get the highest-quality medical and health information.

About The Mesothelioma Center at

  • Assisting mesothelioma patients and their loved ones since 2006.
  • Helps more than 50% of mesothelioma patients diagnosed annually in the U.S.
  • A+ rating from the Better Business Bureau.
  • 5-star reviewed mesothelioma and support organization.
Learn More About Us


"My family has only the highest compliment for the assistance and support that we received from The Mesothelioma Center. This is a staff of compassionate and knowledgeable individuals who respect what your family is experiencing and who go the extra mile to make an unfortunate diagnosis less stressful. Information and assistance were provided by The Mesothelioma Center at no cost to our family."
Mesothelioma patient’s daughter
  • Google Review Rating
  • BBB Review Rating

How to Cite’s Article


Hall, M. (2020, October 16). New Drug Combination Yields Disappointing Results in Mesothelioma Clinical Trial. Retrieved January 28, 2023, from


Hall, Mark. "New Drug Combination Yields Disappointing Results in Mesothelioma Clinical Trial.", 16 Oct 2020,


Hall, Mark. "New Drug Combination Yields Disappointing Results in Mesothelioma Clinical Trial." Last modified October 16, 2020.

Results from a recent Phase II clinical trial found that adding bevacizumab to the common mesothelioma treatment combination of gemcitabine and cisplatin did not improve survival times for malignant mesothelioma patients.

The study, headed by mesothelioma specialist Hedy L. Kindler, M.D., and published in an upcoming issue of the Journal of Clinical Oncology, was conducted by researchers from 11 of the country’s top cancer research facilities.

The double-blind, randomized, placebo-controlled test was designed to determine whether bevacizumab could increase the effectiveness of gemcitabine and cisplatin, two chemotherapy drugs that have been used to treat mesothelioma for years.

Bevacizumab is known to be an anti-Vascular endothelial growth factor (VEGF) antibody. VEGFs assist in the development of blood vessels, cell growth and division and are considered signal proteins.

Researchers were hopeful that the combination treatment could extend survival times of patients with this aggressive cancer.

Mesothelioma affects nearly 3,000 Americans each year and has no known cure. Asbestos is the only known cause of this disease.

Digging Deeper in the Study

One hundred fifteen patients were enrolled in this clinical trial, but only 108 were evaluable. At the 11 different study locations, patients received 1250 mg of gemcitabine, 75 mg of cisplatin and 15 mg of bevacizumab.

Gemcitabine was administered on days 1 and 8 and every 21 days. Cisplatin was given every 21 days and bevacizumab or a placebo was administered every 21 days for six cycles. From there, bevacizumab was provided every 21 days until the cancer progressed.

The median progression-free survival (PFS) time was 6.9 months for patients who received bevacizumab and 6.0 months for patients on the placebo.

The median overall survival (OS) times were 15.6 and 14.7 for bevacizumab and placebo patients, respectively.

Even though slight increases in PFS and OS were demonstrated in the double-blind study, research metrics determine that the results were not statistically significant.

Authors of the study include Theodore G. Karrison, David R. Gandara, Charles Lu, Lee M. Krug and 12 others.

Despite these disappointing results, all hope is not lost for mesothelioma patients. Other experimental treatment options have shown more promising alternatives.

Encouraging Treatment Options

Recent developments in mesothelioma research show bright spots for mesothelioma patients and the entire medical community.

For example, mesothelioma experts like Raffit Hassan have stated that breakthrough drugs like SS1 may be able to add months to patients’ lives if correct combinations are discovered.

“We’re starting to see some very exciting results,” Hassan said.

Furthermore, researchers from the University of Sydney have found that other anti-cancer drugs may also provide the key to treating aggressive diseases and cancers. The study, conducted by professor Des Richardson of the Sydney Medical School, illustrate that drugs can control the spread and growth of cancer cells.

“This will present a significant step forward in the fight against cancer and provide cancer sufferers new hope for a better outcome,” Professor Richardson said.

Finally, thoracic surgeon Dr. Robert Cameron recently spoke at a mesothelioma symposium about the positive benefits of lung-sparing pleurectomy/decortication (P/D) surgery, when compared to the more-dangerous extrapleural pneumonectomy treatment.

“My philosophy has always been ‘do no harm.’ Taking out a lung does harm and there is absolutely no benefit to the patient,” Cameron says on the Pacific Meso Center website.

Clinical trials across the country are continually experimenting with additional mesothelioma treatment options that may one day provide the key to eliminating this rare cancer. Patients should remain positive and proactively seek out treatment options, both experimental and proven, that are suitable to their specific cancer diagnosis.

Connect with a Mesothelioma Doctor
Find a Top Specialist Near You